ImmunityBio, Inc. (IBRX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about ImmunityBio, Inc. (IBRX)
Go deeper and ask any question about IBRX
Company Performance
Current Price
as of Sep 13, 2024$3.58
P/E Ratio
N/A
Market Cap
$2.49B
Description
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerIBRX
- Price$3.58+2.58%
Trading Information
- Market Cap$2.49B
- Float22.90%
- Average Daily Volume (1m)2,771,965
- Average Daily Volume (3m)3,071,387
- EPS-$0.93
Company
- Revenue$1.31M
- Rev Growth (1yr)2,453.66%
- Net Income-$134.56M
- Gross Margin-320.82%
- EBITDA Margin-9,066.57%
- EBITDA-$94.93M
- EV$5.12B
- EV/Revenue3,917.00
- P/EN/A
- P/S1,880.15
Documents
SEC Filings
Factset Street Account
Wikipedia